AI-Driven Clinical Trial Patient Matching & Protocol Compliance

Identifying qualified candidates for complex phase-III oncology trials is one of the most expensive bottlenecks in drug development. Over 80% of clinical trials experience delays due to slow patient recruitment, primarily because patient data is trapped in unstructured clinical notes, pathology PDFs, and lab reports across legacy Electronic Health Record (EHR) systems.

This case study examines how a global pharmaceutical network deployed a multimodal LLM pipeline to parse unstructured medical records and automate trial protocol inclusion matching.

The Compliance & Privacy Architecture

Deploying AI on clinical patient data requires strict adherence to international health governance frameworks (HIPAA in the US, GDPR in Europe, and FDA 21 CFR Part 11 for electronic records).

To satisfy regulatory auditors, the deployment enforced three architectural invariants:

1. Protected Health Information (PHI) De-identification: A specialized local NER (Named Entity Recognition) model strips patient names, addresses, and social security numbers prior to context window assembly.
2. On-Premise / VPC Boundary: All LLM inference executes inside a dedicated HIPAA-compliant VPC with zero external data retention agreements.
3. Deterministic Audit Provenance: Every candidate match recommendation generates an immutable cryptographic hash linking the protocol inclusion criterion to the exact sentence offset in the clinical note.

Multimodal Protocol Matching Pipeline

Trial protocols contain complex inclusion and exclusion logic (e.g., "Patient must have stage-III NSCLC with EGFR exon 19 deletion, prior chemotherapy treatment within 12 months, and ALT/AST levels < 2.5x upper limit of normal").

Standard keyword search fails because medical concepts are expressed variably across clinical notes. The LLM pipeline evaluates inclusion criteria through a multi-stage workflow:

1. Entity Extraction: Parses gene mutations, lab values, prior therapies, and ECOG performance status scores.
2. Logic Verification: Evaluates temporal constraints (e.g., verifying lab tests occurred within the specified 30-day window).
3. Eligibility Scoring: Computes an overall match confidence score (Eligible, Potentially Eligible - Missing Lab, Ineligible).

| Clinical Criterion | Model Parsing Strategy | Verification Rule | |---|---|---| | EGFR Mutation Status | Multimodal PDF Pathology Extraction | Exact Genomic Match | | Organ Function (ALT/AST) | Structured Lab Table Parser | Numerical Value Threshold | | Prior Therapy Window | Temporal Extraction Agent | Date Interval Validation |

Quantified Outcomes

Across a pilot trial covering 54,000 patient records across 12 medical centers:

• Recruitment Speed: Candidate identification rate increased by 68%, reducing phase-III enrollment duration by 4 months.
• Efficiency: Coordinator screening time dropped from 45 minutes per chart down to 6 minutes.
• Compliance: Zero unhandled PHI leaks were detected during independent third-party cybersecurity audits.

Decision Framework

Enterprise healthcare organizations should deploy LLM trial matching when recruitment delays impact trial completion or when manual screening costs exceed $500 per patient chart. If medical records cannot be stripped of PHI locally or if the clinical site lacks a secure VPC deployment boundary, traditional manual coordinator screening must remain mandatory.